Description

Rezonativ (Anti-D Human Immunoglobulin) Solution for Injections 625 IU/ml. 2 ml. Ampoule №1

Ingredients

• Rezonativ contains anti-D human immunoglobulin as the active ingredient.

Dosage

• The recommended dosage of Rezonativ is determined by a healthcare professional based on the patient’s condition. It is typically administered via injection.

Indications

• Rezonativ is indicated for the prevention of hemolytic disease of the newborn (HDN) in Rh D-negative pregnant women.

Contraindications

• Do not use Rezonativ if you have a history of severe allergic reactions to human immunoglobulins.

Directions

• Follow the instructions provided by your healthcare provider for the proper administration of Rezonativ. It is usually given as an intramuscular injection.

Scientific Evidence

• Studies have shown that anti-D immunoglobulin therapy, such as Rezonativ, is highly effective in preventing the development of HDN in Rh D-negative pregnant women. Research published in the Journal of Perinatal Medicine demonstrated a significant reduction in the incidence of HDN with the use of anti-D immunoglobulins.

Additional Information

• It is important to note that Rezonativ should only be administered under the supervision of a healthcare professional. Before using this medication, inform your doctor about any existing medical conditions or medications you are taking.
• Clinical trials have also shown that Rezonativ has a good safety profile with minimal side effects, making it a reliable option for the prevention of HDN.